期刊
TRENDS IN BIOTECHNOLOGY
卷 34, 期 1, 页码 36-48出版社
ELSEVIER SCIENCE LONDON
DOI: 10.1016/j.tibtech.2015.10.005
关键词
-
资金
- Portuguese Funding scheme (Fundacao para a Ciencia e Tecnologia, FCT) [SFRH/BPD/94466/2013, IF/01010/2013]
- Marie Sklodowska-Curie Research and Innovation Staff Exchange (MSCA-RISE) [644167 - INPACT, H2020-MSCA-RISE-2014]
Recombinant antibodies are an emerging class of therapeutics with substantial promise to treat central nervous system (CNS) diseases such as Alzheimer's, Parkinson's, stroke, and brain cancers. However, poor blood-brain barrier (BBB) permeability hinders the progress of antibody therapies for conditions in which the target is located in the brain. Nonetheless, antibodies can nowadays be engineered to enhance their therapeutic applications and translocation of the BBB using the natural portals of the brain. This paper reviews advances in the development and engineering of therapeutic BBB-crossing antibodies and their high potential for treatment of CNS disorders.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据